Methods: A multicenter cohort study was conducted, including patients with biopsy-proven CHB, MASLD, and MASLD combined with CHB from 11 medical centers
Patches deliver medication through the skin over extended periods, with application site affecting absorption rate similar to injection sites
Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
J Trace Elem Med Biol, 2023
These effects are particularly relevant given the overlap between OSA, obesity, and cardiometabolic disease